E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Functional recovary after total hip arthroplasty |
|
E.1.1.1 | Medical condition in easily understood language |
Herstel na een totale heupprothese |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Musculoskeletal Diseases [C05] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Determine whether peri-operative intravenous glucocorticoids aid in the recovery after THA. |
|
E.2.2 | Secondary objectives of the trial |
Post-operative nausea and vomiting (PONV)
Same day mobilization
Time to ability to do stairs
Time to driving a car
Patient questionnaires: Oxford Hip Score; WOMAC; HOOS; Forgotten Joint Score; SF-36; Fatigue Severity scale; VAS pain day / night / exercises; VAS stiffness
Use of analgesia
Use of anti-emetics
Complications: wound healing problems; Infections; allergic reactions; venous Trombo-embolisms (VTE); side effects
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- All patients undergoing unilateral uncemented THA for primary OA of AVN of the hip under general anesthesia (GA)
- Aged 18 years and above (including women of child bearing age)
- Able to provide informed consent
|
|
E.4 | Principal exclusion criteria |
- Younger than 18 years
- Known alcohol or drug abuse
- Known allergy for glucocorticoids
- Administration of any glucocorticoids in the last three months
- Usage of strong analgesia (such as lyrica, oxycodone) as regular medication
- Usage of medication with anticipated interactions with glucocorticoids
- Known gastric ulcer
- Insulin dependent diabetes mellitus
- Severe heart disease (NYHA > 2)
- Liver or renal failure
- Systemic rheumatoid diseases
- Insufficient understanding of the Dutch language
- Unable to provide informed consent
- Pre-operative use of walking aids
- Gross anatomical deformities
- Significant intra-operative complication such as peri-prosthetic fracture
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Average number of steps per day during one week before total hip arthroplastyand the first 6 weeks after total hip arthroplasty |
|
E.5.2 | Secondary end point(s) |
Post-operative nausea and vomiting
Same day mobilization
Time to ability to do stairs
Time to driving a car
Patient questionnaires: Oxford Hip Score; WOMAC; HOOS; Forgotten Joint Score; SF-36; Fatigue Severity Scale; VAS pain day / night / exercises; VAS stiffness
Use of analgesia
Use of anti-emetics
Complications :Wound healing problems; Infections; Allergic reactions; Venous Trombo-embolisms (VTE)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Post-operative nausea and vomiting: after surgery day 0, day 1, day 2, day 3, day 4, day 5
Same day mobilization: after surgery day 0
Time to ability to do stairs: day 0, day 1, day 2, day 3, day 4, day 5, day 6, day 7
Time to driving a car:
Patient questionnaires: Oxford Hip Score; WOMAC; HOOS; Forgotten Joint Score; EQ 5D; Fatigue Severity Scale; VAS pain day / night / exercises; VAS stiffness
Use of analgesia:
Use of anti-emetics
Complications :Wound healing problems; Infections; Allergic reactions; Venous Trombo-embolisms (VTE)
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |